Hyderabad, June 22 -- : Aurobindo Pharma USA, Inc., a wholly owned subsidiary of Aurobindo Pharma, has received approval from the U.S. Federal Trade Commission (FTC) to proceed with its acquisition of Lannett Company for $250 million on a cash-free, debt-free basis, including normalized working capital.
The transaction is expected to be completed before the end of June 2026, Hyderabad based pharma company said in a release here on Monday.
Pennsylvania-based Lannett develops and commercialises a diversified portfolio of complex, non-opioid controlled-substance generic medicines.
The acquisition is expected to strengthen Aurobindo USA's presence in this segment while adding a manufacturing facility in the United States to its network.
Lan...